Cargando…

Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Aims/Introduction:  Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods:  Seru...

Descripción completa

Detalles Bibliográficos
Autores principales: Senmaru, Takafumi, Fukui, Michiaki, Kobayashi, Kanae, Iwase, Hiroya, Inada, Shinobu, Okada, Hiroshi, Asano, Mai, Yamazaki, Masahiro, Hasegawa, Goji, Nakamura, Naoto, Iwasaki, Masahiro, Yabe, Daisuke, Kurose, Takeshi, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015428/
https://www.ncbi.nlm.nih.gov/pubmed/24843614
http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x
_version_ 1782315336581775360
author Senmaru, Takafumi
Fukui, Michiaki
Kobayashi, Kanae
Iwase, Hiroya
Inada, Shinobu
Okada, Hiroshi
Asano, Mai
Yamazaki, Masahiro
Hasegawa, Goji
Nakamura, Naoto
Iwasaki, Masahiro
Yabe, Daisuke
Kurose, Takeshi
Seino, Yutaka
author_facet Senmaru, Takafumi
Fukui, Michiaki
Kobayashi, Kanae
Iwase, Hiroya
Inada, Shinobu
Okada, Hiroshi
Asano, Mai
Yamazaki, Masahiro
Hasegawa, Goji
Nakamura, Naoto
Iwasaki, Masahiro
Yabe, Daisuke
Kurose, Takeshi
Seino, Yutaka
author_sort Senmaru, Takafumi
collection PubMed
description Aims/Introduction:  Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods:  Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs. Results:  Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c. Conclusions:  DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012)
format Online
Article
Text
id pubmed-4015428
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-40154282014-05-19 Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations Senmaru, Takafumi Fukui, Michiaki Kobayashi, Kanae Iwase, Hiroya Inada, Shinobu Okada, Hiroshi Asano, Mai Yamazaki, Masahiro Hasegawa, Goji Nakamura, Naoto Iwasaki, Masahiro Yabe, Daisuke Kurose, Takeshi Seino, Yutaka J Diabetes Investig Articles Aims/Introduction:  Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes. Materials and Methods:  Serum EPA concentrations were measured in 62 consecutive patients with type 2 diabetes who were newly given DPP‐4 inhibitor as a monotherapy or as an add‐on therapy to oral hypoglycemic agents. The dosage of oral hypoglycemic agents was maintained during the observation period. After 24 weeks of treatment with DPP‐4 inhibitor, we evaluated the relationships between a decrease in hemoglobin A1c from baseline and serum EPA concentrations, as well as age, sex, body mass index (BMI), hemoglobin A1c at baseline and usage of antidiabetic concomitant drugs. Results:  Hemoglobin A1c was significantly decreased from 8.1 ± 1.1% to 7.2 ± 1.0% by DPP‐4 inhibitor. A decrease in hemoglobin A1c correlated with BMI (r = −0.396, P = 0.0013), age (r = 0.275, P = 0.0032), hemoglobin A1c at baseline (r = 0.490, P < 0.0001) and log EPA (r = 0.285, P = 0.0246). Multiple regression analysis showed that BMI (β = −0.419, P = 0.0002), hemoglobin A1c at baseline (β = 0.579, P < 0.0001) and log EPA (β = 0.220, P = 0.0228) were independent determinants of decrease in hemoglobin A1c. Conclusions:  DPP‐4 inhibitor is effective in patients with type 2 diabetes with high serum EPA concentrations. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00220.x , 2012) Blackwell Publishing Ltd 2012-05-22 2012-12-20 /pmc/articles/PMC4015428/ /pubmed/24843614 http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x Text en © 2012 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd
spellingShingle Articles
Senmaru, Takafumi
Fukui, Michiaki
Kobayashi, Kanae
Iwase, Hiroya
Inada, Shinobu
Okada, Hiroshi
Asano, Mai
Yamazaki, Masahiro
Hasegawa, Goji
Nakamura, Naoto
Iwasaki, Masahiro
Yabe, Daisuke
Kurose, Takeshi
Seino, Yutaka
Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title_full Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title_fullStr Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title_full_unstemmed Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title_short Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
title_sort dipeptidyl‐peptidase iv inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015428/
https://www.ncbi.nlm.nih.gov/pubmed/24843614
http://dx.doi.org/10.1111/j.2040-1124.2012.00220.x
work_keys_str_mv AT senmarutakafumi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT fukuimichiaki dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT kobayashikanae dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT iwasehiroya dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT inadashinobu dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT okadahiroshi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT asanomai dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT yamazakimasahiro dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT hasegawagoji dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT nakamuranaoto dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT iwasakimasahiro dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT yabedaisuke dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT kurosetakeshi dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations
AT seinoyutaka dipeptidylpeptidaseivinhibitoriseffectiveinpatientswithtype2diabeteswithhighserumeicosapentaenoicacidconcentrations